

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.unpto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/667,534	09/22/2003	Adan Rios	RIOS:004USC2/10311652	9949
32425 FULBRIGHT	7590 12/18/200 & JAWORSKI L.L.P.	EXAMINER		
600 CONGRE SUITE 2400	SS AVE.		PARKIN, JEFFREY S	
AUSTIN, TX	78701		ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			12/18/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/667,534 RIOS, ADAN Office Action Summary Examiner Art Unit 1648 Jeffrey S. Parkin -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO WHICHEVER IS LONGER, FROM THE MAILING DATE OF THI Extension of time may be available under the provisions of 37 CFR 1.136(a). In no even after SIX (6) MONTHS from the making date of the communication. Failure to reply within the sol or centred period for reply with by static, cause the applica Any reply received by the Office later than three months after the mailing date of this come amend patter therm adjustment. See 37 CFR 1.704(b).	S COMMUNICATION. I, however, may a reply be timely filed expire SIX (6) MONTHS from the mailing date of this communication. ation to become ABANDONED (35 U.S.C. § 133).
Status	
1) Responsive to communication(s) filed on 25 August 2009.	
2a)☑ This action is FINAL. 2b)☐ This action is no	n-final.
3) Since this application is in condition for allowance except for	or formal matters, prosecution as to the merits is
closed in accordance with the practice under Ex parte Qua	yle, 1935 C.D. 11, 453 O.G. 213.
Disposition of Claims	
4) Claim(s) 48 and 57-64 is/are pending in the application.	
4a) Of the above claim(s) is/are withdrawn from con-	sideration.
5) Claim(s) is/are allowed.	
6)⊠ Claim(s) <u>48 and 57-64</u> is/are rejected.	
7) Claim(s) is/are objected to.	
8) Claim(s) are subject to restriction and/or election red	quirement.
Application Papers	
9)☐ The specification is objected to by the Examiner.	
10) The drawing(s) filed on is/are: a) accepted or b) □	objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be	held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required	• • • • • • • • • • • • • • • • • • • •
11)☐ The oath or declaration is objected to by the Examiner. Not	e the attached Office Action or form PTO-152.
Priority under 35 U.S.C. § 119	
12) Acknowledgment is made of a claim for foreign priority under a) All b) Some * c) None of:	er 35 U.S.C. § 119(a)-(d) or (f).
1. Certified copies of the priority documents have been	received.
2. Certified copies of the priority documents have been	received in Application No
Copies of the certified copies of the priority documer	nts have been received in this National Stage
application from the International Bureau (PCT Rule	17.2(a)).
* See the attached detailed Office action for a list of the certification	ed copies not received.
Attachment(s)	
National Reference Cited (PTO 000)	4) Intension Common (DTO 412)

01	п	44.45	

Notice of References Cited (PTO-892)	Interview Summary (PTO-413)
Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal Patent Application
Paper No/e\/Mail Date	6) Other

Detailed Office Action

Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 25 August, 2009. Claims 48 and 57-64 are pending in the instant application.

Nonstatutory Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 U.S.P.O.2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 U.S.P.O.2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 U.S.P.Q. 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 U.S.P.O. 761 (C.C.P.A. 1982); In re Vogel, 422 F.2d 438, 164 U.S.P.Q. 619 (C.C.P.A. 1970); and In re Thorington, 418 F.2d 528, 163 U.S.P.O. 644 (C.C.P.A. 1969). A timely filed terminal disclaimer in compliance with 37 C.F.R. § 1.321(c) or § 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is

shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 C.F.R. § 3.73(b).

Claims 48 and 57-60 are rejected on the ground nonstatutory obviousness-type double patenting as unpatentable over claims 11-13 and 15-17 of U.S. Patent No. 6,383,806 (Rios, 2002). Although the conflicting claims are not identical, they are not patentably distinct from each other. The claims of the instant application are directed toward a method of eliciting an immune response comprising administering a viral particle wherein the RT has been inactivated through binding to an azido-labeled compound and irradiation. Claims 40 and 41 recite specific azido-labels. Claim 42 recites UV irradiation. and 44 specify the virus is HIV or HIV-1. respectively. Claims 11-13 and 15-17 of the '806 patent are directed toward a method of inducing an immune response in a host by administering HIV viral particles that have been inactivated through azido-labeled compounds and UV irradiation. Accordingly, the claims of the '806 patent clearly anticipate the claimed subject matter of the instant application.

Claims 61-64 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 11-13 and 15-17 of U.S. Patent No. 6,383,806 (Rios, 2002), and further in view of Ferrari et al. (1997). Although the conflicting claims are not identical, they are not

patentably distinct from each other. Claims 44-47 of the instant application provide additional embodiments pertaining to the origins and strain of HIV employed (e.g., Group M, subtype or clade B). Ferrari et al. (1997) discuss the importance of developing cross-clade immune responses against HIV to provide a more effective immunogen. Therefore, it would have been prima facie obvious at the time filing to prepare inactivated HIV-1 virions, using the Method of Rios, from multiple clades, as suggested by Ferrari et al. (1997), since this would provide a more efficacious immunogen.

Response to Arguments

Applicant submitted a terminal disclaimer (TD) in an attempt to obviate the rejection. However, the TD filed on 25 August, 2009, disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of 6,383,806 has been reviewed and is **NOT** accepted. An attorney or agent, not of record, is not authorized to sign a terminal disclaimer in the capacity as an attorney or agent acting in a representative capacity as provided by 37 C.F.R. § 1.34 (a). See 37 C.F.R. § 1.321(b) and/or (c). Applicant should resubmit the TD along with a suitable power of attorney.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. \S 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set

forth the best mode contemplated by the inventor of carrying out his invention.

Enablement

The previous rejection of claims 49 and 50 under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement, is hereby withdrawn in response to applicant's amendment.

Action Is Final

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 C.F.R. § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Larry R. Helms, can be reached at (571) 272-0803. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600.

Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

/Jeffrey S. Parkin/ Primary Examiner, Art Unit 1648

16 December, 2009